JERUSALEM — Teva on Tuesday said that a trial date has been set for its ongoing patent infringement litigation against several drug makers.
Teva said the U.S. District Court for the Southern District of New York will commence proceedings Sept. 7. Teva's litigation is against Momenta Pharmaceuticals/Sandoz and Mylan Pharmaceuticals/Mylan/Natco Pharma regarding their purported generic versions of Copaxone (glatiramer acetate injection).
"We are very pleased to have a trial date as we are confident we will prevail in this litigation,” said Richard Egosi, Teva’s chief legal officer. “Teva remains committed to vigorously defending its intellectual property rights against infringement.”